Company / Free Cash Flow
ALNYLAM PHARMACEUTICALS, INC. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$465.4M
FY2025
5-year range
-$685.3M / $465.4M
FY2021-FY2025
Trend
+1192.7%
vs FY2024
Sector context
#25 of 194
Health Care
What the data says
Free Cash Flow changed +1193% YoY in FY2025, a notable deviation from the 9-year average annual change of +110%.
Based on SEC 10-K filings.
$465M in FY2025. Top quartile in the Health Care sector.
Improved from $42M to $465M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 194This company $465.4M Sector average $470.8M
▼
-1.2% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 1192.7% year-over-year.
- Ranks #25 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $465.4M | +1192.7% |
| FY2024 | -$42.6M | -201.5% |
| FY2023 | $41.9M | +106.1% |
| FY2022 | -$685.3M | -63.7% |
| FY2021 | -$418.6M | +39.3% |
| FY2020 | -$689.5M | -41.6% |
| FY2019 | -$487.0M | -30.8% |
| FY2018 | -$372.3M | +23.6% |
| FY2017 | -$487.0M | -30.8% |
| FY2016 | -$372.3M | -84.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026